Seasonique

See also: Generic Seasonale

Seasonique is a brand name of ethinyl estradiol/levonorgestrel, approved by the FDA in the following formulation(s):

SEASONIQUE (ethinyl estradiol; levonorgestrel - tablet; oral)

• 
  Manufacturer: TEVA WOMENS
  
  Approval date: May 25, 2006
  
  Strength(s): 0.03MG,0.01MG;0.15MG,N/A ^[RLD][AB]

Has a generic version of Seasonique been approved?

A generic version of Seasonique has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Seasonique and have been approved by the FDA:

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL (ethinyl estradiol; levonorgestrel tablet; oral)

• 
  Manufacturer: WATSON LABS
  
  Approval date: May 31, 2011
  
  Strength(s): 0.03MG,0.01MG;0.15MG,N/A ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Seasonique. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
  Patent 7,320,969
  Issued: January 22, 2008
  Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
  Assignee(s): Duramed Pharmaceuticals, Inc.
  This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
  
  Patent expiration dates:
  
  
  • January 30, 2024
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
  
  



• 
  Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
  Patent 7,615,545
  Issued: November 10, 2009
  Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
  Assignee(s): Duramed Pharmaceuticals, Inc.
  This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
  
  Patent expiration dates:
  
  
  • June 15, 2023
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  



• 
  Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
  Patent 7,855,190
  Issued: December 21, 2010
  Inventor(s): Bell; Robert G. & Ben-Maimon; Carole S. & Iskold; Beata & Bronnenkant; Lance J. & Hait; Howard & Reape; Kathleen Z.
  Assignee(s): Teva Women's Health, Inc.
  The present invention provides contraceptive regimens in which a female is administered a combined dosage form of estrogen and progestin followed by a period of administration of estrogen. The disclosed contraceptive regimens can be administered to a female as a method of providing non-contraceptive benefits.
  
  Patent expiration dates:
  
  
  • December 5, 2028
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  



• 
  Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
  Patent 7,858,605
  Issued: December 28, 2010
  Inventor(s): Bell; Robert G. & Ben-Maimon; Carole & Iskold; Beata
  Assignee(s): Teva Women's Health, Inc.
  This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
  
  Patent expiration dates:
  
  
  • June 23, 2023
    
    ✓ 
    Drug product
  
  

See also...

• Seasonique Consumer Information (Drugs.com)
• Seasonique Consumer Information (Wolters Kluwer)
• Seasonique extended-cycle Consumer Information (Cerner Multum)
• Levonorgestrel/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and levonorgestrel Consumer Information (Cerner Multum)
• Ethinyl estradiol and levonorgestrel extended-cycle Consumer Information (Cerner Multum)